爱美医疗 FOLD 深 沪
已收盘 03-27 16:00:00 美东时间
14.41
-0.020
-0.14%
华盛通- 最 高14.43
- 今 开14.43
- 成交量 228.89万股
- 最 低 14.41
- 昨 收 14.43
- 总市值 45.25亿
- 52周最高 14.43
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 5.51
- 委 比 64.56%
- 总股本 3.14亿
- 历史最高 25.39
- 量 比 0.55
- 振 幅 0.14%
- 历史最低 1.765
- 每 手 1
- 风险率 3.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多新浪财经ESG：爱美医疗 MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:13
Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares
Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares Bradley L. Campbell, President and CEO and a director of Amicus Therapeutics Inc., reported a disposal of common shares. The full filing can be accessed through the link below. Disclaimer: This news brief was created
03-05 08:55
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
03-02 19:10
Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks
Amicus Therapeutics (FOLD) has disclosed a new risk, in the Litigation & Le...
02-22 14:05
财报速睇 | 爱美医疗 2025财年Q4营收1.85亿美元，同比增长23.7%；归母净利润0.02亿美元，同比下滑88.5%
华盛资讯2月21日讯，爱美医疗公布2025财年Q4业绩，公司Q4营收1.85亿美元，同比增长23.7%，归母净利润0.02亿美元，同比下滑88.5%。
02-21 05:17
Amicus Therapeutics Q4 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $185.213M Beat $179.764M Estimate
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 by 19.05 percent. This is a 11.11 percent increase over earnings of $0.09 per share from
02-21 05:05
BRIEF-Amicus Therapeutics Q4 Revenue USD 185.2 Million Vs. IBES Estimate USD 180.7 Million
BRIEF-Amicus Therapeutics Q4 Revenue USD 185.2 Million Vs. IBES Estimate USD 180.7 Million Feb 20 (Reuters) - Amicus Therapeutics Q4 net income USD 1.7 million. Q4 EPS USD 0.01
02-21 05:01
Amicus Therapeutics präsentiert neue Langzeitdaten zu Galafold und Pombiliti + Opfolda
Amicus Therapeutics präsentiert neue Langzeitdaten zu Galafold und Pombiliti + Opfolda Amicus Therapeutics Inc. hat die Präsentation neuer Daten aus klinischen und Real-World-Studien zu Galafold® (Migalastat) für die Behandlung der Fabry-Krankheit sowie zu POMBILITI® (Cipaglucosidase alfa) + OPFOLDA
02-03 21:01
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Amicus Therapeutics announced new data from clinical and real-world studies of Galafold and Pombiliti + Opfolda in Fabry and late-onset Pompe diseases at the 22nd Annual WORLD Symposium 2026. The data highlight long-term efficacy and safety, with Galafold showing benefits in Fabry patients and Pombiliti + Opfolda demonstrating improvements in muscle function and biomarkers in Pompe patients. The company emphasized its commitment to advancing trea...
02-03 13:00
Top 3 Health Care Stocks That May Implode In Q1
As of Feb. 2, 2026, three stocks in the health care sector could be flashing a ...
02-02 18:29
